147 related articles for article (PubMed ID: 38355149)
1. CDK4/6 inhibitors in lung cancer: current practice and future directions.
Lv S; Yang J; Lin J; Huang X; Zhao H; Zhao C; Yang L
Eur Respir Rev; 2024 Jan; 33(171):. PubMed ID: 38355149
[TBL] [Abstract][Full Text] [Related]
2. [Research Progress of CDK4/6 Inhibitors in Non-small Cell Lung Cancer].
Qin Q; Ren Y; Zhong D
Zhongguo Fei Ai Za Zhi; 2020 Mar; 23(3):176-181. PubMed ID: 32102134
[TBL] [Abstract][Full Text] [Related]
3. A unique CDK4/6 inhibitor: Current and future therapeutic strategies of abemaciclib.
Chong QY; Kok ZH; Bui NL; Xiang X; Wong AL; Yong WP; Sethi G; Lobie PE; Wang L; Goh BC
Pharmacol Res; 2020 Jun; 156():104686. PubMed ID: 32068118
[TBL] [Abstract][Full Text] [Related]
4. CDK4/6 inhibition synergizes with inhibition of P21-Activated Kinases (PAKs) in lung cancer cell lines.
Wright GM; Gimbrone NT; Sarcar B; Percy TR; Gordián ER; Kinose F; Sumi NJ; Rix U; Cress WD
PLoS One; 2021; 16(6):e0252927. PubMed ID: 34138895
[TBL] [Abstract][Full Text] [Related]
5. In vitro antitumor properties of a novel cyclin-dependent kinase inhibitor, P276-00.
Joshi KS; Rathos MJ; Joshi RD; Sivakumar M; Mascarenhas M; Kamble S; Lal B; Sharma S
Mol Cancer Ther; 2007 Mar; 6(3):918-25. PubMed ID: 17363486
[TBL] [Abstract][Full Text] [Related]
6. Down-regulation of RCC1 sensitizes immunotherapy by up-regulating PD-L1 via p27
Zeng X; Zhong M; Yang Y; Wang Z; Zhu Y
J Cell Mol Med; 2021 Apr; 25(8):4136-4147. PubMed ID: 33630417
[TBL] [Abstract][Full Text] [Related]
7. Do CDK4/6 inhibitors have potential as targeted therapeutics for squamous cell cancers?
Kalu NN; Johnson FM
Expert Opin Investig Drugs; 2017 Feb; 26(2):207-217. PubMed ID: 28042706
[TBL] [Abstract][Full Text] [Related]
8. A CDK4/6 inhibitor enhances cytotoxicity of paclitaxel in lung adenocarcinoma cells harboring mutant KRAS as well as wild-type KRAS.
Zhang XH; Cheng Y; Shin JY; Kim JO; Oh JE; Kang JH
Cancer Biol Ther; 2013 Jul; 14(7):597-605. PubMed ID: 23792647
[TBL] [Abstract][Full Text] [Related]
9. Cyclin-Dependent Kinase 4/6 Inhibitors: A Potential Breakthrough Therapy for Malignancies of Gastrointestinal Tract.
Zeng F; Zhou Y; Khowtanapanich T; Saengboonmee C
In Vivo; 2022; 36(4):1580-1590. PubMed ID: 35738597
[TBL] [Abstract][Full Text] [Related]
10. Palbociclib, a selective CDK4/6 inhibitor, enhances the effect of selumetinib in RAS-driven non-small cell lung cancer.
Zhou J; Zhang S; Chen X; Zheng X; Yao Y; Lu G; Zhou J
Cancer Lett; 2017 Nov; 408():130-137. PubMed ID: 28866094
[TBL] [Abstract][Full Text] [Related]
11. MiR-34b-3p represses cell proliferation, cell cycle progression and cell apoptosis in non-small-cell lung cancer (NSCLC) by targeting CDK4.
Feng H; Ge F; Du L; Zhang Z; Liu D
J Cell Mol Med; 2019 Aug; 23(8):5282-5291. PubMed ID: 31199581
[TBL] [Abstract][Full Text] [Related]
12. Enhanced antitumor effect of alectinib in combination with cyclin-dependent kinase 4/6 inhibitor against
Fujimura T; Furugaki K; Harada N; Yoshimura Y
Cancer Biol Ther; 2020 Sep; 21(9):863-870. PubMed ID: 32835580
[TBL] [Abstract][Full Text] [Related]
13. Targeting CDK4/6 in patients with cancer.
Hamilton E; Infante JR
Cancer Treat Rev; 2016 Apr; 45():129-38. PubMed ID: 27017286
[TBL] [Abstract][Full Text] [Related]
14. Targeting the cyclin D-cyclin-dependent kinase (CDK) 4/6-retinoblastoma pathway with selective CDK 4/6 inhibitors in hormone receptor-positive breast cancer: rationale, current status, and future directions.
Spring L; Bardia A; Modi S
Discov Med; 2016 Jan; 21(113):65-74. PubMed ID: 26896604
[TBL] [Abstract][Full Text] [Related]
15. CDK4/6 inhibitor-SHR6390 exerts potent antitumor activity in esophageal squamous cell carcinoma by inhibiting phosphorylated Rb and inducing G1 cell cycle arrest.
Wang J; Li Q; Yuan J; Wang J; Chen Z; Liu Z; Li Z; Lai Y; Gao J; Shen L
J Transl Med; 2017 Jun; 15(1):127. PubMed ID: 28578693
[TBL] [Abstract][Full Text] [Related]
16. Mitochondrial creatine kinase 1 regulates the cell cycle in non-small cell lung cancer via activation of cyclin-dependent kinase 4.
Yang M; Wang X; Ye Z; Liu T; Meng Y; Duan Y; Yuan X; Yue X; Deng W; Liu RY
Respir Res; 2023 Apr; 24(1):111. PubMed ID: 37061730
[TBL] [Abstract][Full Text] [Related]
17. MiR-613 induces cell cycle arrest by targeting CDK4 in non-small cell lung cancer.
Li D; Li DQ; Liu D; Tang XJ
Cell Oncol (Dordr); 2016 Apr; 39(2):139-47. PubMed ID: 26744345
[TBL] [Abstract][Full Text] [Related]
18. eIF4A Inhibitors Suppress Cell-Cycle Feedback Response and Acquired Resistance to CDK4/6 Inhibition in Cancer.
Kong T; Xue Y; Cencic R; Zhu X; Monast A; Fu Z; Pilon V; Sangwan V; Guiot MC; Foulkes WD; Porco JA; Park M; Pelletier J; Huang S
Mol Cancer Ther; 2019 Nov; 18(11):2158-2170. PubMed ID: 31395685
[TBL] [Abstract][Full Text] [Related]
19. Proliferative suppression by CDK4/6 inhibition: complex function of the retinoblastoma pathway in liver tissue and hepatoma cells.
Rivadeneira DB; Mayhew CN; Thangavel C; Sotillo E; Reed CA; Graña X; Knudsen ES
Gastroenterology; 2010 May; 138(5):1920-30. PubMed ID: 20100483
[TBL] [Abstract][Full Text] [Related]
20. Stapled peptide targeting the CDK4/Cyclin D interface combined with Abemaciclib inhibits KRAS mutant lung cancer growth.
Bouclier C; Simon M; Laconde G; Pellerano M; Diot S; Lantuejoul S; Busser B; Vanwonterghem L; Vollaire J; Josserand V; Legrand B; Coll JL; Amblard M; Hurbin A; Morris MC
Theranostics; 2020; 10(5):2008-2028. PubMed ID: 32104498
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
